Ontario Teachers Pension Plan Board Has $2.96 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Ontario Teachers Pension Plan Board trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 29.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,728 shares of the biopharmaceutical company’s stock after selling 15,107 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Gilead Sciences were worth $2,964,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Heritage Wealth Management LLC lifted its holdings in Gilead Sciences by 54.6% in the fourth quarter. Heritage Wealth Management LLC now owns 368 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 130 shares during the period. Sanctuary Wealth Management L.L.C. bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $33,000. SJS Investment Consulting Inc. lifted its stake in shares of Gilead Sciences by 187.9% in the 1st quarter. SJS Investment Consulting Inc. now owns 403 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 263 shares during the period. Venturi Wealth Management LLC bought a new position in shares of Gilead Sciences in the 1st quarter worth $36,000. Finally, BerganKDV Wealth Management LLC grew its stake in shares of Gilead Sciences by 41.9% during the first quarter. BerganKDV Wealth Management LLC now owns 440 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 130 shares during the period. 82.33% of the stock is owned by institutional investors.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $80.00, for a total transaction of $400,000.00. Following the completion of the transaction, the chief financial officer now directly owns 107,587 shares of the company’s stock, valued at $8,606,960. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Gilead Sciences news, CFO Andrew D. Dickinson sold 5,000 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the sale, the chief financial officer now directly owns 107,587 shares of the company’s stock, valued at $8,606,960. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Merdad Parsey sold 1,485 shares of Gilead Sciences stock in a transaction dated Tuesday, June 13th. The shares were sold at an average price of $76.90, for a total transaction of $114,196.50. Following the completion of the transaction, the insider now directly owns 29,402 shares of the company’s stock, valued at approximately $2,261,013.80. The disclosure for this sale can be found here. 0.21% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on GILD. StockNews.com began coverage on Gilead Sciences in a report on Thursday, August 17th. They set a “strong-buy” rating on the stock. Cantor Fitzgerald reduced their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 19th. Barclays lowered their target price on shares of Gilead Sciences from $81.00 to $80.00 and set an “equal weight” rating for the company in a research note on Monday, July 24th. Morgan Stanley increased their target price on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock an “equal weight” rating in a report on Friday, August 4th. Finally, Royal Bank of Canada boosted their price target on shares of Gilead Sciences from $83.00 to $84.00 and gave the company a “sector perform” rating in a report on Friday, August 4th. Eight equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $90.50.

Gilead Sciences Stock Down 0.7 %

NASDAQ GILD traded down $0.57 during trading on Tuesday, hitting $76.08. The stock had a trading volume of 1,223,081 shares, compared to its average volume of 5,748,688. Gilead Sciences, Inc. has a 12 month low of $61.44 and a 12 month high of $89.74. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.91 and a current ratio of 1.02. The company’s 50-day moving average price is $77.34 and its two-hundred day moving average price is $79.20. The company has a market capitalization of $94.80 billion, a PE ratio of 17.66, a P/E/G ratio of 0.86 and a beta of 0.37.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.30). The business had revenue of $6.60 billion during the quarter, compared to the consensus estimate of $6.45 billion. Gilead Sciences had a return on equity of 37.53% and a net margin of 20.03%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.58 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 6.63 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be issued a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 3.94%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s payout ratio is 68.97%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.